Tiziana Life Sciences announced that a preclinical study published on bioRxiv on April 16 demonstrated that its intranasal anti‑CD3 antibody, foralumab, significantly reduced neuroinflammation in a mouse model of Long COVID. The preprint, titled “Intranasal Anti‑CD3 Antibody Treatment Attenuates Post‑COVID Neuroinflammation and Enhances Hippocampal Neurogenesis and Cognitive Function in Mice,” reports that foralumab increased regulatory T cells in the brain, restored hippocampal neurogenesis, and improved short‑term memory.
The study also found that Long COVID patients with neurological symptoms have lower circulating Treg levels, suggesting that the drug’s mechanism of action may translate to human disease. Because foralumab is the only fully human anti‑CD3 monoclonal antibody in clinical development, the data reinforce the company’s broader therapeutic strategy across neuroinflammatory conditions such as multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis.
CEO Ivor Elrifi said, “We are thrilled to see these robust preclinical data in BioRxiv, further validating the broad therapeutic potential of our intranasal foralumab platform. Foralumab is the only fully human anti‑CD3 monoclonal antibody in clinical development, and these results directly support the mechanistic foundation for our ongoing programs in non‑active secondary progressive multiple sclerosis, MSA, Alzheimer’s disease, and ALS.” The company is currently conducting clinical trials for foralumab in several indications and has recently raised capital to fund ongoing research and development.
The preprint is not yet peer‑reviewed, and the findings remain preliminary. However, the data provide a promising proof‑of‑concept that intranasal delivery can modulate neuroinflammation and cognitive deficits in a disease model that mimics Long COVID, a condition with a large unmet medical need.
The announcement underscores the potential of Tiziana’s intranasal platform to address a spectrum of neuroinflammatory disorders, positioning the company to advance foralumab through clinical development and potentially expand its pipeline beyond Long COVID.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.